Hostname: page-component-7b7567c8c-wxvwp Total loading time: 0 Render date: 2026-11-17T03:58:52.534Z Has data issue: false hasContentIssue false

89 Milestone meta-analysis for survival data: A case study in first-line Mrcc

Published online by Cambridge University Press:  08 May 2026

Pratik Reddy
Affiliation:
Clinical & Translational Science Program, Graduate School of Graduate Biomedical Sciences, Tufts University, Boston, MA 02111, USA
Ludovic Trinquart
Affiliation:
Clinical & Translational Science Program, Graduate School of Graduate Biomedical Sciences, Tufts University, Boston, MA 02111, USACenter for Clinical Trials, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA 02111, USATufts CTSI
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the 'Save PDF' action button.

Objectives/Goals: To develop a novel meta-analysis model that estimates pooled risk ratios (RR) at prespecified milestones, accounts for unequal follow-up across trials, and leverages between-time correlation, thereby providing clinically interpretable estimates under potential non-proportional hazards (PH). Methods/Study Population: Our model combines study-specific RRs – the ratios of cumulative event probabilities – from Kaplan-Meier curves at prespecified times (12, 24, 36 months, etc.). Using the delta method, we derive within-trial variances for log-RRs and cross-time covariances to reflect correlation among milestones. These study-level estimates and variance-covariance matrices enter a multivariate random effects model to obtain pooled RRs. We illustrate this method with a meta-analysis of progression-free survival in 7 randomized clinical trials of first-line therapy immunotherapy combinations in metastatic renal cell carcinoma. Results/Anticipated Results: Follow-up for PFS across the 7 trials was heterogeneous: all 7 trials contribute at 12 months, 6 at 24 months, 5 at 36 months, 4 at 48 months, and only 2 contributing at 54 and 60 months. This heterogeneity motivates a multivariate approach that borrows strength across times. PH diagnostics indicate deviations from PH for PFS in 3 trials, supporting the need for pooled effects at milestones rather than a single summary measure. We will report pooled RRs at 12, 24, 36, 48, 54, and 60 months. We expect the multivariate model to improve precision at shared milestones while honestly reflecting increasing uncertainty at sparse later times. Discussion/Significance of Impact: When follow-up differs across trials and PH is questionable, a multivariate RR meta-analysis preserves interpretability and efficiently uses all available milestones without forcing a single-number summary. This approach clarifies when benefits accrue and provide clinically interpretable results.

Information

Type
Biostatistics, epidemiology, and research design
Creative Commons
Creative Common License - CCCreative Common License - BYCreative Common License - NCCreative Common License - ND
This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work.
Copyright
© The Author(s), 2026. The Association for Clinical and Translational Science